On 28th February 2023, Stayble Therapeutics AB announced that the Company received approval to initiate the first clinical trial of its disc herniation candidate. The Company is broadening its activities by initiating a new project with STA363, targeting the indication lumbar disc herniation (“LDH”). A Phase 2b clinical trial is already underway in the indication degenerative disc disease (“DDD”).
Read more: